Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up

• Autors principals: Antonio Lacquaniti (Autor), Patrizio Pasqualetti (Autor), Teresa Casuscelli di Tocco (Autor), Susanna Campo (Autor), Stefania Rovito (Autor), Maurizio Bucca (Autor), Antonino Ragusa (Autor), Paolo Monardo (Autor)
• Format: Llibre
• Publicat: The Korean Society of Nephrology, 2020-09-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have...